You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Patient characteristics at diagnosis

From: Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study

  Combined group   EBRT + Boost SBRT alone
Age at diagnosis   No. patients (%) P value No. patients No. patients
  40-49 1 (1.0)   0 1
  50-59 13 (13.4)   9 4
  60-69 31 (32.0)   12 19
  70-79 39 (40.2)   20 19
  80-89 13 (13.4)   4 9
Mean (range)   70.0 (43.2-85.7) 0.039 69.5 (50.6-84.4) 70.3 (43.2-85.7)
PSA level at treatment   ng/mL    
Combined Mean (range) 14.4 (0.59-53.1)   14.7 14.2
  Median 11.5 0.0056 12 11.25
PSA level at diagnosis   No. patients    
  <4 ng/mL 5 (5.2)   1 4
  4-10 ng/mL 30 (30.9)   17 13
  >10-20 ng/mL 39 (40.2)   16 23
  >20 ng/mL 23 (23.7)   11 12
Clinical stage      
  T1c 73 (75.2) 0.22 33 40
  T2x 2 (2.1)   2 0
  T2a 18 (18.6)   6 12
  T2b 2 (2.1)   2 0
  T2c 2 (2.1)   2 0
Gleason score    0.55   
  6 4 (4.1)   1 3
  7 (3 + 4) 15 (15.5)   7 8
  7 (4 + 3) 16 (16.5)   7 9
  8 46 (47.4)   22 24
  9 16 (16.5)   8 8
Hormone treatment    0.34   
  No 43 (44.3)   17 26
  Yes 54 (55.7)   28 26
RT treatment    0.86   
  SBRT 52 (53.6)    
  EBRT + SBRT 45 (46.4)    
High risk assessment: criteria    0.95   
Gleason ≥ 8 or PSA > 20   83 (85.6)   45 38
Multiple adverse factors*:   14 (14.4)   0 14
  1. *Per NCCN 2013, patients with multiple adverse factors can be shifted into the high risk group (T2b-T2c, Gleason score 7, PSA 10–20 ng/mL).